empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“Empagliflozin did not affect IL-6 (ETR: 1.03, 95% CI 0.82-1.30, p = 0.78) or hsCRP (ETR: 1.15, 95% CI 0.87-1.51, p = 0.33) compared to placebo.”
Quoted verbatim from The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.. - Study
- RCT
- Duration
- 6 months
- Dose
- 10 mg
- Population
- Outpatients without diabetes with BMI above 28 kg/m2 and risk factors for heart failure, empagliflozin 10 mg versus placebo
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.2026PMID:42286641Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against C-reactive protein concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR77M406W9ECRYCY916GSQ